Coryx Throat
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Registration
- Applicants
- 1
- Registrations
- 1
- Schedule source
- SAHPRA documentation
Applicants and registrations
Variants
Regulatory status
Where S1 sits on the scale
Sold by a pharmacist, no doctor's prescription needed.
Schedule 1 medicines are normally sold by a pharmacist, or by a supervised pharmacist intern or assistant, without a doctor's visit; a veterinarian, or a licensed dispensing doctor, dentist or nurse prescriber, may also supply them. A nurse or other non-doctor prescriber may only prescribe the specific substances the Schedule names for that purpose, and may only dispense them if licensed to do so. A child under 12 may only be sold one of these medicines on a prescription, or on a written order that names the purpose and carries a signature the seller recognises.
Schedule S1, read from the product's PI-PIL leaflet.
The Consolidated Schedules list this ingredient up to S4; the leaflet's S1 applies to this product.
Who may supply: A pharmacist, or a supervised pharmacist intern or assistant; manufacturers and wholesalers supplying people who may lawfully possess it; a veterinarian, who may prescribe, compound or dispense it; a medical practitioner or dentist, who may prescribe it, and may compound or dispense it only if licensed under section 22C(1)(a); a nurse or other registered non-doctor prescriber, who may prescribe only the Scheduled substances the Schedule identifies for that purpose, and dispense them if licensed to do so; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Benzocaine, chlorhexidine gluconate solution
S4: Benzocaine
- when intended for ophthalmic or parenteral use;
- except in lozenges containing 30 milligrams or less of benzocaine, per dosage unit; (S1)
- except when intended for topical use; (S1)
- except in preparations containing 2 percent or less of benzocaine. (S1)
Consolidated Schedules 06 July 2026, lines 5467 to 5475
S1: Benzocaine
- when intended for topical use;
- in oral preparations containing 2 percent or less of benzocaine;
- in lozenges containing 30 milligrams or less of benzocaine, per dosage unit;
- except when intended for ophthalmic or parenteral use. (S4)
Consolidated Schedules 06 July 2026, lines 156 to 164
S1: Chlorhexidine
- when intended for human vaginal use.
Consolidated Schedules 06 July 2026, line 320
Pharmacological class: Surface anaesthetics. (class 16.3)
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
Schedule Verification
Coryx throat, Cipla Medpro (Pty) Ltd is scheduled S1 in its official SAHPRA documents, read with 90% confidence.
These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.